title: [Early detection of cancer therapeutics-related cardiac dysfunction].
abstract: Anthracyclines and molecular targeted agents have improved prognosis of patients undergoing chemotherapeutics for malignancy. However, the use of these therapies is limited because of risk of cardiac toxicity. The severity of the cardiomyopathy can range from an asymptomatic left ventricular (LV) dysfunction to a severe congestive heart failure. Cardiomyopathy can be reversible or irreversible according to the type of chemotherapy, modality of administration and patient's characteristics. Several studies aimed to early detection and the evaluation of tools to characterize patients at risk to develop cardiac side effects in order to prevent severe LV dysfunction. According to this literature, it is recommended that initial assessment and follow-up of patients undergoing these chemotherapies be performed using troponin dosage, assessment of left ventricle ejection fraction and evaluation of LV myocardial deformation assessing LV global longitudinal strain.
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Agathe
authors.initials: A
authors.lastname: Potier
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Ederhy
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Yann
authors.initials: Y
authors.lastname: Ancedy
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Etienney
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Laurie
authors.initials: L
authors.lastname: Soulat-Dufour
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Chauvet
authors.affiliation: DITEP, Gustave-Roussy Cancer Campus, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Hollebecque
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Saroumadi
authors.initials: S
authors.lastname: Adavane-Scheuble
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Boccara
authors.affiliation: DITEP, Gustave-Roussy Cancer Campus, France.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
authors.affiliation: AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France; Unité INSERM 856 «Thrombose, athérothrombose et pharmacologie appliquée», 75013 Paris, France. Electronic address: ariel.cohen@aphp.fr.
authors.forename: Ariel
authors.initials: A
authors.lastname: Cohen
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D007211:Indoles / Q000009:adverse effects; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D000077157:Sorafenib; D000077210:Sunitinib; D000068878:Trastuzumab / Q000009:adverse effects; D014336:Troponin / Q000032:analysis
chemical_list: D018943:Anthracyclines; D007211:Indoles; D010671:Phenylurea Compounds; D011758:Pyrroles; D014336:Troponin; D009536:Niacinamide; D000077157:Sorafenib; D000068878:Trastuzumab; D000077210:Sunitinib
keywords: Anthracycline; Cardio-oncolgy; Cardio-oncology; Cardiotoxicity; Molecular targeted agent; Thérapies moléculaires ciblées; Toxicité cardiaque; Troponin